MiNK Therapeutics Inc INKT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if INKT is a good fit for your portfolio.
News
-
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
-
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
-
MiNK Reports Fourth Quarter and Year-End 2023 Results
-
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
-
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
-
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
Trading Information
- Previous Close Price
- $0.93
- Day Range
- $0.92–0.95
- 52-Week Range
- $0.75–3.34
- Bid/Ask
- $0.92 / $0.99
- Market Cap
- $32.27 Mil
- Volume/Avg
- 29 / 97,268
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 1.48%
Company Profile
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 37
- Website
- https://www.minktherapeutics.com
Comparables
Valuation
|
Metric
|
INKT
|
ITOS
|
VOR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 0.77 | 0.79 |
Price/Sales | — | 34.95 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
INKT
ITOS
VOR
Financial Strength
|
Metric
|
INKT
|
ITOS
|
VOR
|
|---|---|---|---|
Quick Ratio | 0.30 | 13.46 | 8.81 |
Current Ratio | 0.32 | 13.76 | 9.04 |
Interest Coverage | — | — | — |
Quick Ratio
INKT
ITOS
VOR
Profitability
|
Metric
|
INKT
|
ITOS
|
VOR
|
|---|---|---|---|
Return on Assets (Normalized) | −151.68% | −12.92% | −41.83% |
Return on Equity (Normalized) | — | −14.67% | −51.69% |
Return on Invested Capital (Normalized) | — | −18.54% | −47.03% |
Return on Assets
INKT
ITOS
VOR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zpynbnjwl | Llfnt | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lvpdpftm | Vvdkn | $105.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Brrgtwxc | Mydclc | $105.3 Bil | |
MRNA
| Moderna Inc | Fzlfvkv | Tpfm | $46.7 Bil | |
ARGX
| argenx SE ADR | Xnfmqlrdz | Tnxh | $23.5 Bil | |
BNTX
| BioNTech SE ADR | Crxqwkcwc | Hrljw | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ttsxlqpx | Spxhh | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Blsrhftfq | Bysmbjq | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qydbbbpvn | Qrjbqx | $12.6 Bil | |
INCY
| Incyte Corp | Fbxxlhyx | Ckggwt | $12.0 Bil |